Drug Trial Radar · NCT06450197
Phase IIa Study Evaluating AZD7798 in Crohn's Disease
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
120
Actual
Start
Aug 28, 2024
Primary completion
Apr 30, 2026
Study completion May 14, 2027
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jun 10, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomised, double-blind, parallel group, placebo-controlled Phase IIa study designed to evaluate the efficacy and safety of AZD7798 in participants with moderate to severe Crohn's disease.
Conditions
- Moderate to Severe Crohn's Disease
Interventions
AZD7798Drug
AZD7798
PlaceboOther
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- CDAI remissionTime frame: Week 12
Locations
116 sites in 26 countries. Site status is shown where the registry gives one.
Research Site
Phoenix, Arizona
Research Site
Escondido, California
Research Site
La Jolla, California
Research Site
Orlando, Florida
Research Site
Idaho Falls, Idaho
Research Site
Kansas City, Kansas
Research Site
Clinton Township, Michigan
Research Site
St Louis, Missouri
Research Site
Asheville, North Carolina
Research Site
Charlotte, North Carolina
Research Site
Uniontown, Pennsylvania
Research Site
Garland, Texas
Research Site
San Antonio, Texas
Research Site
CABA, Argentina
Research Site
CABA, Argentina
Research Site
Ciudad Autonoma de Bs As, Argentina
Research Site
Ciudad de Buenos Aires, Argentina
Research Site
San Miguel de Tucumán, Argentina
Research Site
Adelaide, Australia
Research Site
Box Hill, Australia
Research Site
Fitzroy, Australia
Research Site
Melbourne, Australia
Research Site
Wollongong, Australia
Research Site
Leuven, Belgium
Research Site
Campinas, Brazil
Research Site
Jaú, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Santo André, Brazil
Research Site
São José do Rio Preto, Brazil
Research Site
São Paulo, Brazil
Research Site
Gorna Oryahovitsa, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Lethbridge, Alberta, Canada
Research Site
Santiago, Chile
Research Site
Santiago, Chile
Research Site
Santiago, Chile
Research Site
Viña del Mar, Chile
Research Site
Beijing, China
Research Site
Chengdu, China
Showing 40 of 116 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.